Loreley Calvet

885 total citations
11 papers, 319 citations indexed

About

Loreley Calvet is a scholar working on Oncology, Cell Biology and Molecular Biology. According to data from OpenAlex, Loreley Calvet has authored 11 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Cell Biology and 4 papers in Molecular Biology. Recurrent topics in Loreley Calvet's work include Hippo pathway signaling and YAP/TAZ (3 papers), Neuroblastoma Research and Treatments (3 papers) and Cancer-related Molecular Pathways (3 papers). Loreley Calvet is often cited by papers focused on Hippo pathway signaling and YAP/TAZ (3 papers), Neuroblastoma Research and Treatments (3 papers) and Cancer-related Molecular Pathways (3 papers). Loreley Calvet collaborates with scholars based in France, Netherlands and Germany. Loreley Calvet's co-authors include Patricia Vrignaud, François Lavelle, Alain Commerçon, Hervé Bouchard, Pascale Lejeune, Jean‐François Riou, Cécile Combeau, Dorothée Sémiond, Marie-Christine Bissery and Jackie Morizet and has published in prestigious journals such as Angewandte Chemie International Edition, Cancer Research and Oncogene.

In The Last Decade

Loreley Calvet

11 papers receiving 315 citations

Peers

Loreley Calvet
Chiara Barozzi Italy
Timothy A. Yap United Kingdom
M. McNamara United States
Rukh Yusuf United States
Raquel Luque Spain
Xu–Ting Zhi China
Caterina Malcontenti‐Wilson Australia
Sandra Ictech United States
Karianne G. Fleten Norway
Cathy E. Nolan United States
Chiara Barozzi Italy
Loreley Calvet
Citations per year, relative to Loreley Calvet Loreley Calvet (= 1×) peers Chiara Barozzi

Countries citing papers authored by Loreley Calvet

Since Specialization
Citations

This map shows the geographic impact of Loreley Calvet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loreley Calvet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loreley Calvet more than expected).

Fields of papers citing papers by Loreley Calvet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loreley Calvet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loreley Calvet. The network helps show where Loreley Calvet may publish in the future.

Co-authorship network of co-authors of Loreley Calvet

This figure shows the co-authorship network connecting the top 25 collaborators of Loreley Calvet. A scholar is included among the top collaborators of Loreley Calvet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loreley Calvet. Loreley Calvet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Calvet, Loreley, Emmanuel Spanakis, Jean-Christophe Le Bail, et al.. (2022). YAP1 is essential for malignant mesothelioma tumor maintenance. BMC Cancer. 22(1). 639–639. 12 indexed citations
2.
Spanakis, Emmanuel, Loreley Calvet, Colette Dib, et al.. (2021). Abstract 2161: A transcriptomic signature for measuring YAP1 activity in patient samples and tumor models. Cancer Research. 81(13_Supplement). 2161–2161. 2 indexed citations
3.
Calvet, Loreley, Emmanuel Spanakis, Isabelle Sanchez, et al.. (2020). Abstract 4858: Oncogenic HIPPO-YAP1: in vivo target validation of YAP1 in malignant mesothelioma. Cancer Research. 80(16_Supplement). 4858–4858. 1 indexed citations
4.
Calvet, Loreley, Anne‐Marie Lefebvre, Céline Nicolazzi, et al.. (2016). Abstract 1197: Outstanding preclinical efficacy of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 in patient-derived xenograft solid tumors. Cancer Research. 76(14_Supplement). 1197–1197. 4 indexed citations
5.
Wenzel, Silke C., Holger Hoffmann, Jidong Zhang, et al.. (2015). Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure–Activity Relationships. Angewandte Chemie International Edition. 54(51). 15560–15564. 35 indexed citations
6.
Égile, Coumaran, Jean‐Paul Nicolas, Elisa Francesconi, et al.. (2014). The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET -Amplified Cancer. Molecular Cancer Therapeutics. 14(2). 384–394. 23 indexed citations
7.
Vrignaud, Patricia, Dorothée Sémiond, Pascale Lejeune, et al.. (2013). Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors. Clinical Cancer Research. 19(11). 2973–2983. 191 indexed citations
8.
Goulaouic, Hélène, Jean‐Paul Nicolas, Loreley Calvet, et al.. (2012). Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial. Cancer Research. 72(8_Supplement). 845–845. 1 indexed citations
9.
Calvet, Loreley, Birgit Geoerger, Marie Regairaz, et al.. (2006). Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan. Oncogene. 25(22). 3150–3159. 18 indexed citations
10.
Calvet, Loreley, Alexandre Santos, A. Valent, et al.. (2004). No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. British Journal of Cancer. 91(6). 1205–1212. 13 indexed citations
11.
Santos, Alexandre, Loreley Calvet, Marie-Josée Terrier-Lacombe, et al.. (2004). In Vivo Treatment with CPT-11 Leads to Differentiation of Neuroblastoma Xenografts and Topoisomerase I Alterations. Cancer Research. 64(9). 3223–3229. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiara Barozzi Breakdown of academic impact, for papers by Timothy A. Yap Breakdown of academic impact, for papers by M. McNamara Breakdown of academic impact, for papers by Rukh Yusuf Breakdown of academic impact, for papers by Raquel Luque Breakdown of academic impact, for papers by Xu–Ting Zhi Breakdown of academic impact, for papers by Caterina Malcontenti‐Wilson Breakdown of academic impact, for papers by Sandra Ictech Breakdown of academic impact, for papers by Karianne G. Fleten Breakdown of academic impact, for papers by Cathy E. Nolan
Rankless by CCL
2026